Log in
NASDAQ:UTHR

United Therapeutics Competitors

$135.54
+0.47 (+0.35 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$134.29
Now: $135.54
$135.86
50-Day Range
$104.01
MA: $127.99
$142.93
52-Week Range
$75.58
Now: $135.54
$144.26
Volume113,254 shs
Average Volume509,672 shs
Market Capitalization$6.02 billion
P/E Ratio13.92
Dividend YieldN/A
Beta0.71

Competitors

United Therapeutics (NASDAQ:UTHR) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying UTHR stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to United Therapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Amgen and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
United Therapeutics30.04%14.90%10.64%

Analyst Ratings

This is a summary of current recommendations for Amgen and United Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
United Therapeutics11602.63

Amgen currently has a consensus target price of $254.08, indicating a potential upside of 13.02%. United Therapeutics has a consensus target price of $146.00, indicating a potential upside of 7.72%. Given Amgen's higher possible upside, analysts plainly believe Amgen is more favorable than United Therapeutics.

Valuation & Earnings

This table compares Amgen and United Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.60$7.84 billion$14.8215.17
United Therapeutics$1.45 billion4.16$-104,500,000.00($2.39)-56.71

Amgen has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amgen has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

71.7% of Amgen shares are owned by institutional investors. Comparatively, 94.4% of United Therapeutics shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 10.9% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Amgen beats United Therapeutics on 10 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Gilead Sciences and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
United Therapeutics30.04%14.90%10.64%

Analyst Recommendations

This is a breakdown of current ratings for Gilead Sciences and United Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151002.30
United Therapeutics11602.63

Gilead Sciences presently has a consensus target price of $76.1538, indicating a potential upside of 26.86%. United Therapeutics has a consensus target price of $146.00, indicating a potential upside of 7.72%. Given Gilead Sciences' higher possible upside, equities research analysts clearly believe Gilead Sciences is more favorable than United Therapeutics.

Valuation and Earnings

This table compares Gilead Sciences and United Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.35$5.39 billion$6.149.78
United Therapeutics$1.45 billion4.16$-104,500,000.00($2.39)-56.71

Gilead Sciences has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Gilead Sciences has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are held by institutional investors. Comparatively, 94.4% of United Therapeutics shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 10.9% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Gilead Sciences beats United Therapeutics on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Vertex Pharmaceuticals and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
United Therapeutics30.04%14.90%10.64%

Analyst Recommendations

This is a breakdown of current ratings for Vertex Pharmaceuticals and United Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals082212.77
United Therapeutics11602.63

Vertex Pharmaceuticals presently has a consensus target price of $290.5862, indicating a potential upside of 28.18%. United Therapeutics has a consensus target price of $146.00, indicating a potential upside of 7.72%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vertex Pharmaceuticals is more favorable than United Therapeutics.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and United Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion14.16$1.18 billion$4.2952.85
United Therapeutics$1.45 billion4.16$-104,500,000.00($2.39)-56.71

Vertex Pharmaceuticals has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 94.4% of United Therapeutics shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats United Therapeutics on 13 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Regeneron Pharmaceuticals and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals37.30%26.71%19.39%
United Therapeutics30.04%14.90%10.64%

Analyst Recommendations

This is a breakdown of current ratings for Regeneron Pharmaceuticals and United Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0101312.63
United Therapeutics11602.63

Regeneron Pharmaceuticals presently has a consensus target price of $628.52, indicating a potential upside of 22.27%. United Therapeutics has a consensus target price of $146.00, indicating a potential upside of 7.72%. Given Regeneron Pharmaceuticals' higher possible upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than United Therapeutics.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and United Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.98$2.12 billion$21.4723.94
United Therapeutics$1.45 billion4.16$-104,500,000.00($2.39)-56.71

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 94.4% of United Therapeutics shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats United Therapeutics on 12 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Biogen and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
United Therapeutics30.04%14.90%10.64%

Analyst Recommendations

This is a breakdown of current ratings for Biogen and United Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151302.24
United Therapeutics11602.63

Biogen presently has a consensus target price of $305.9032, indicating a potential upside of 25.48%. United Therapeutics has a consensus target price of $146.00, indicating a potential upside of 7.72%. Given Biogen's higher possible upside, equities research analysts clearly believe Biogen is more favorable than United Therapeutics.

Valuation and Earnings

This table compares Biogen and United Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.61$5.89 billion$33.577.26
United Therapeutics$1.45 billion4.16$-104,500,000.00($2.39)-56.71

Biogen has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biogen has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

78.9% of Biogen shares are held by institutional investors. Comparatively, 94.4% of United Therapeutics shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 10.9% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Biogen beats United Therapeutics on 8 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares Seagen and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen-25.17%-18.32%-15.49%
United Therapeutics30.04%14.90%10.64%

Institutional & Insider Ownership

92.0% of Seagen shares are held by institutional investors. Comparatively, 94.4% of United Therapeutics shares are held by institutional investors. 31.1% of Seagen shares are held by insiders. Comparatively, 10.9% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Seagen and United Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million33.26$-158,650,000.00($1.33)-127.16
United Therapeutics$1.45 billion4.16$-104,500,000.00($2.39)-56.71

United Therapeutics has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Seagen and United Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
United Therapeutics11602.63

Seagen presently has a consensus target price of $176.75, indicating a potential upside of 4.51%. United Therapeutics has a consensus target price of $146.00, indicating a potential upside of 7.72%. Given United Therapeutics' higher possible upside, analysts clearly believe United Therapeutics is more favorable than Seagen.

Volatility & Risk

Seagen has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Summary

United Therapeutics beats Seagen on 8 of the 15 factors compared between the two stocks.


United Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$224.81+2.0%$130.88 billion$23.36 billion18.13Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.9$60.03+0.9%$75.25 billion$22.45 billion61.89Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$226.71+3.8%$58.95 billion$4.16 billion28.63
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$514.05+1.1%$54.85 billion$7.86 billion19.90
Biogen logo
BIIB
Biogen
2.0$243.78+0.8%$37.51 billion$14.38 billion8.07Analyst Revision
Seagen logo
SGEN
Seagen
1.4$169.12+2.2%$30.49 billion$916.71 million-112.00Analyst Downgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.0$123.83+0.7%$27.10 billion$4.99 billion28.93
Incyte logo
INCY
Incyte
1.5$83.25+2.5%$18.23 billion$2.16 billion-53.03
Exact Sciences logo
EXAS
Exact Sciences
1.6$118.19+2.0%$17.78 billion$876.29 million-53.48
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$129.86+3.4%$15.09 billion$219.75 million-16.58Analyst Report
Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$80.40+2.8%$14.60 billion$1.70 billion18.40
Repligen logo
RGEN
Repligen
1.4$186.99+3.0%$9.84 billion$270.24 million322.40
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.56+0.5%$8.93 billion$788.10 million45.29Analyst Downgrade
Novavax logo
NVAX
Novavax
1.8$125.69+18.4%$8.00 billion$18.66 million-45.71
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$51.13+1.7%$7.15 billion$1.12 billion106.52Insider Selling
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$23.24+2.1%$6.06 billion$182.24 million-20.21
Exelixis logo
EXEL
Exelixis
1.9$19.41+3.5%$6.02 billion$967.78 million40.44Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.23+2.3%$5.44 billion$195.99 million251.44Analyst Report
Insider Selling
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$82.83+2.9%$4.39 billion$1.11 billion26.63
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$55.81+3.2%$3.86 billion$36.13 million-83.30
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+0.6%$3.83 billion$806.43 million-9.33
Alkermes logo
ALKS
Alkermes
1.3$18.50+0.4%$2.94 billion$1.17 billion-40.22
OPKO Health logo
OPK
OPKO Health
1.9$4.13+4.4%$2.77 billion$901.90 million-12.51
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.83+1.7%$1.89 billion$428.41 million17.14
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$119.11+6.0%$1.84 billionN/A-10.76
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$10.12+3.5%$1.43 billion$102.43 million-12.19
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$85.92+1.7%$1.38 billion$120.28 million-86.79
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$17.78+2.4%$1.34 billion$638.60 million-6.63
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$37.27+0.3%$1.23 billion$252 million-3.60
Innoviva logo
INVA
Innoviva
1.1$10.85+2.7%$1.10 billion$261.02 million5.54
Codexis logo
CDXS
Codexis
1.1$18.01+0.8%$1.07 billion$68.46 million-51.46
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.52+4.0%$1.04 billion$82.27 million-12.84Analyst Upgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$5.13+7.2%$905.78 million$48.83 million-6.75
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$22.75+4.4%$900.15 million$3.57 million-10.20
MannKind logo
MNKD
MannKind
0.9$3.08+4.2%$716.41 million$63.04 million-14.67
Agenus logo
AGEN
Agenus
1.6$3.71+5.4%$705.45 million$150.05 million-3.40
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.73+3.6%$690.21 million$109.33 million-3.88
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.2$12.41+2.4%$678.73 million$227.19 million5.94Analyst Downgrade
Heavy News Reporting
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.50+0.1%$650.03 million$38.19 million37.50
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.91+0.3%$623.59 million$150,000.00-4.16
Geron logo
GERN
Geron
1.4$1.87+3.2%$580.58 million$460,000.00-5.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.79+11.3%$527.73 million$35.22 million-3.50
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.11+5.8%$525.53 million$59.29 million-22.21
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75+0.0%$477.47 million$327.75 million-1.89
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.12+3.1%$455.67 million$22.27 million-4.47
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.76+6.7%$420.40 million$143.01 million-0.91
XOMA logo
XOMA
XOMA
1.4$32.05+1.9%$353.26 million$18.37 million-28.87Analyst Report
Insider Selling
Verastem logo
VSTM
Verastem
1.5$1.99+14.6%$337.85 million$17.46 million-1.41High Trading Volume
Unusual Options Activity
Heavy News Reporting
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.59+1.2%$295.85 million$54.76 million-1.95
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$2.77+5.8%$259.56 million$36.63 million-3.18
This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.